B. Pharm / sem - VIII (CBSGS) 02/05/16

CLINICAL PH. QP Code : 717401

(2 Hours) [Total Marks : 35

N.B. : (1) **All** *questions are* **compulsory.**
(2) **Figures** to the **right** indicate **full** marks.

1. *Answer the following :* 7
   (i) Define community pharmacy.
   (ii) Enlist any four reasons for patient non-compliance.
   (iii) Classify adverse drug reactions.
   (iv) Justify digitalis toxicity is increased on co-current administration with loop diuertics.
   (v) Enlist name of antimicrobials safe in pregnancy.
   (vi) Enlist categories of drugs which require therapeutic drug monitoring.
   (vii) State any one aim of pharmacovigilance.

2. (a) Answer **any one** of the following: 4
   (i) Define patient counselling. Explain with examples role of hospital pharmacist in patient counselling.
   (ii) Define clinical pharmacy. Explain scope and objectives of clinical pharmacy.

   (b) Answer **any one** of the following : 3
   (i) Write in short methods of assessment of Compliance.
   (ii) Discuss role of pharmacist ensuring rational use of medication.

3. (a) Answer **any one** of the following: 4
   (i) Explain detection and reporting methods of Adverse drug reaction.
   (ii) Explain in brief manifestation of Adverse drug reaction.
   (b) Answer **any one** of the following: 3
   (i) What are the strategies used for therapeutic drug monitoring.
   (ii) Discuss in brief criteria for valid therapeutic drug monitoring.

4. (a) Answer **any one** of the following: 4
   (i) Classify drug interactions. Explain drug interactions due to alterations in metabolism with suitable examples.
   (ii) Write a short note on drug-food interactions.
   (b) Answer **any one** of the following: 3
   (i) Define paediatrics. Explain the factors affecting drug therapy in paediatrics.
   (ii) Discuss dose adjustment in geriatric patient with kidney failure.

5. (a) Answer **any one** of the following: 4
   (i) What is double blind method used in clinical trial. Explain in detail phase III of clinical trial.
   (ii) Explain principles of ICH GCP
   (b) Answer **any one** of the following: 3
   (i) Define the following term
      (a) New drug (as per schedule Y)
      (b) Case report form. (CRF)
      (c) Serious adverse event (SAE)
   (ii) Write a note on Bioequivalence studies.
